Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report)'s stock price rose 14.1% during mid-day trading on Tuesday . The stock traded as high as $3.50 and last traded at $3.54. Approximately 1,998,283 shares were traded during trading, a decline of 47% from the average daily volume of 3,756,978 shares. The stock had previously closed at $3.10.
Wall Street Analysts Forecast Growth
SANA has been the topic of several recent analyst reports. Citizens Jmp upgraded Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price target on the stock in a report on Tuesday, March 18th. Morgan Stanley assumed coverage on Sana Biotechnology in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $12.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $11.00 target price on shares of Sana Biotechnology in a research report on Thursday, April 24th. Jefferies Financial Group started coverage on shares of Sana Biotechnology in a report on Friday, March 14th. They issued a "buy" rating and a $7.00 price target on the stock. Finally, JMP Securities reissued a "market outperform" rating and issued a $5.00 price objective on shares of Sana Biotechnology in a research report on Tuesday, June 24th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $9.17.
Check Out Our Latest Stock Report on SANA
Sana Biotechnology Stock Up 3.0%
The firm has a 50 day moving average price of $2.52 and a 200 day moving average price of $2.46. The stock has a market cap of $942.51 million, a PE ratio of -4.75 and a beta of 1.86.
Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.02. Equities analysts forecast that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.
Hedge Funds Weigh In On Sana Biotechnology
Several institutional investors have recently bought and sold shares of SANA. Boxer Capital Management LLC bought a new stake in Sana Biotechnology during the 4th quarter valued at $2,518,000. Corient Private Wealth LLC lifted its stake in shares of Sana Biotechnology by 161.7% during the 4th quarter. Corient Private Wealth LLC now owns 1,182,699 shares of the company's stock worth $1,928,000 after purchasing an additional 730,699 shares during the last quarter. Millennium Management LLC boosted its position in Sana Biotechnology by 604.8% during the fourth quarter. Millennium Management LLC now owns 728,901 shares of the company's stock valued at $1,188,000 after purchasing an additional 625,481 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Sana Biotechnology by 44.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,557,496 shares of the company's stock valued at $2,538,000 after purchasing an additional 478,596 shares during the last quarter. Finally, Clearline Capital LP purchased a new position in Sana Biotechnology in the first quarter valued at about $690,000. 88.23% of the stock is owned by hedge funds and other institutional investors.
Sana Biotechnology Company Profile
(
Get Free Report)
Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.
Featured Stories
Before you consider Sana Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.
While Sana Biotechnology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.